Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD20/CD30-CAR-T in R/R Lymphoma
NCT06519344Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD20/CD30-CAR-T cells in diffuse large B-cell lymphoma (DLBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma (FL) and 4 more, sponsored by Tongji Hospital. Primary endpoint: Incidence of dose-limiting toxicity at 28 days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Anti-CD20/CD30-CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Primary mediastinal large B-cell lymphoma (PMBCL)Follicular lymphoma (FL)Mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06519344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519344.